BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2020 2:27:20 AM | Browse: 1330 | Download: 2238
Publication Name World Journal of Hepatology
Manuscript ID 58709
Country United States
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Surgery
Manuscript Type Review
Article Title Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma
Manuscript Source Invited Manuscript
All Author List Clifford Akateh, Aslam M Ejaz, Timothy Michael Pawlik and Jordan M Cloyd
ORCID
Author(s) ORCID Number
Clifford Akateh http://orcid.org/0000-0003-2936-9779
Aslam M Ejaz http://orcid.org/0000-0002-1387-2604
Timothy Michael Pawlik http://orcid.org/0000-0002-4828-8096
Jordan M Cloyd http://orcid.org/0000-0002-2373-8433
Funding Agency and Grant Number
Corresponding Author Jordan M Cloyd, MD, Assistant Professor, Department of Surgery, The Ohio State University, 410 W 10th Ave, N-907, Columbus, OH 43210, United States. jordan.cloyd@osumc.edu
Key Words Biliary tract cancer; Preoperative therapy; Conversion therapy; Down-staging; Hepatectomy; Liver resection
Core Tip Liver resection is the primary component of curative-intent treatment for patients with localized intrahepatic cholangiocarcinoma (ICC). However, a majority of patients present with locally advanced disease and even those who undergo resection are at high risk of recurrence. Neoadjuvant therapy may successfully downstage a subset of patients to resectable disease and improve the long-term outcomes of patients treated with multimodality therapy. As such, the benefits of neoadjuvant treatment strategies aimed at down-staging the tumor and increasing resection rates are of great interest. While high-level evidence regarding the efficacy of neoadjuvant therapy in ICC is lacking, emerging evidence from case control series, as well as recent advances in systemic therapies, liver-directed treatments, and targeted therapies based on an improved understanding of cholangiocarcinogenesis have led to increasing interest in its use.
Publish Date 2020-10-24 02:27
Citation Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(10): 693-708
URL https://www.wjgnet.com/1948-5182/full/v12/i10/693.htm
DOI https://dx.doi.org/10.4254/wjh.v12.i10.693
Full Article (PDF) WJH-12-693.pdf
Full Article (Word) WJH-12-693.docx